These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 16135784

  • 1. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
    Gavva NR, Tamir R, Klionsky L, Norman MH, Louis JC, Wild KD, Treanor JJ.
    Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
    [Abstract] [Full Text] [Related]

  • 2. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.
    Klionsky L, Tamir R, Holzinger B, Bi X, Talvenheimo J, Kim H, Martin F, Louis JC, Treanor JJ, Gavva NR.
    J Pharmacol Exp Ther; 2006 Oct; 319(1):192-8. PubMed ID: 16844842
    [Abstract] [Full Text] [Related]

  • 3. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
    Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):377-86. PubMed ID: 12721338
    [Abstract] [Full Text] [Related]

  • 4. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, Chu KL, McDonald HA, Vos M, Niforatos W, Bayburt EK, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR.
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [Abstract] [Full Text] [Related]

  • 5. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
    Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB.
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
    [Abstract] [Full Text] [Related]

  • 6. Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8.
    Weil A, Moore SE, Waite NJ, Randall A, Gunthorpe MJ.
    Mol Pharmacol; 2005 Aug; 68(2):518-27. PubMed ID: 15911692
    [Abstract] [Full Text] [Related]

  • 7. TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats.
    De Schepper HU, De Man JG, Ruyssers NE, Deiteren A, Van Nassauw L, Timmermans JP, Martinet W, Herman AG, Pelckmans PA, De Winter BY.
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G245-53. PubMed ID: 17991707
    [Abstract] [Full Text] [Related]

  • 8. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, Gavva NR.
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [Abstract] [Full Text] [Related]

  • 9. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJ.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
    [Abstract] [Full Text] [Related]

  • 10. Functional study on TRPV1-mediated signalling in the mouse small intestine: involvement of tachykinin receptors.
    de Man JG, Boeckx S, Anguille S, de Winter BY, de Schepper HU, Herman AG, Pelckmans PA.
    Neurogastroenterol Motil; 2008 May; 20(5):546-56. PubMed ID: 18194153
    [Abstract] [Full Text] [Related]

  • 11. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
    Kanai Y, Hara T, Imai A, Sakakibara A.
    J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
    [Abstract] [Full Text] [Related]

  • 12. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
    Bianchi BR, El Kouhen R, Neelands TR, Lee CH, Gomtsyan A, Raja SN, Vaidyanathan SN, Surber B, McDonald HA, Surowy CS, Faltynek CR, Moreland RB, Jarvis MF, Puttfarcken PS.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic antagonism of the oral aversive taste-directed response to capsaicin in a mouse brief access taste aversion assay.
    Long DJ, Devantier HR, Brennan FX, Bryant RW, Salemme FR, Palmer RK.
    J Pharmacol Exp Ther; 2010 Feb; 332(2):525-30. PubMed ID: 19903834
    [Abstract] [Full Text] [Related]

  • 14. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
    El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR.
    J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
    [Abstract] [Full Text] [Related]

  • 15. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats.
    Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A.
    Neuropharmacology; 2005 Dec; 49(7):977-84. PubMed ID: 15998524
    [Abstract] [Full Text] [Related]

  • 16. Cloning and pharmacological characterization of mouse TRPV1.
    Correll CC, Phelps PT, Anthes JC, Umland S, Greenfeder S.
    Neurosci Lett; 2004 Nov 03; 370(1):55-60. PubMed ID: 15489017
    [Abstract] [Full Text] [Related]

  • 17. Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1).
    Phelps PT, Anthes JC, Correll CC.
    Eur J Pharmacol; 2005 Apr 18; 513(1-2):57-66. PubMed ID: 15878709
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
    Kitagawa Y, Miyai A, Usui K, Hamada Y, Deai K, Wada M, Koga Y, Sakata M, Hayashi M, Tominaga M, Matsushita M.
    J Pharmacol Exp Ther; 2012 Aug 18; 342(2):520-8. PubMed ID: 22588258
    [Abstract] [Full Text] [Related]

  • 19. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
    Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K.
    J Pharmacol Exp Ther; 2003 Jul 18; 306(1):387-93. PubMed ID: 12721336
    [Abstract] [Full Text] [Related]

  • 20. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, Kakimoto S, Aoki T, Matsuoka N.
    J Pharmacol Exp Ther; 2011 Mar 18; 336(3):743-50. PubMed ID: 21098091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.